Evidence map›Paper›PMID 37077859›Full record

ArticleOncoscience2023

Mitochondrial regulator ATAD3A: a molecular determinant favoring head and neck cancer development.

Yong Teng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yong TengDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, School of Medicine, Atlanta, GA 30322, USA.

Funding

ATAD3A as a Novel Target in Head and Neck CancerR01DE028351 · NIDCR · EMORY UNIVERSITY · PI TENG, YONG · 2019 to 2023
$1.9M
Role of FAT1 somatic mutations in aggressiveness of head and neck cancerR03DE032084 · NIDCR · EMORY UNIVERSITY · PI CHEN, ZHENGJIA, TENG, YONG · 2022 to 2023
$328k
The Impact of Arf1 on Hypoxia Signaling and Oral CancerR03DE028387 · NIDCR · EMORY UNIVERSITY · PI TENG, YONG · 2019 to 2020
$306k
NIDCR NIH HHS R01 DE028351NIDCR NIH HHS R03 DE028387NIDCR NIH HHS R03 DE032084
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-cancer targetATAD3AcancerERK1/2mitochondria

Identifiers

PMID37077859
PMCPMC10109270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.